Top Markets
Coin of the day
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Rangering i aksjer #41009
MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm,... MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm, primarily focused on the creation of innovative therapeutic agents and research tools. Their efforts are directed towards addressing a range of medical challenges, including neurological conditions, liver ailments, various types of cancer, and applications within interventional cardiology and peripheral vascular health. The company's product pipeline features several key developments: MCT-125: This investigational therapy is currently in Phase II clinical trials, targeting the primary fatigue commonly associated with multiple sclerosis. MCT-465: A preclinical-stage synthetic double-stranded RNA (dsRNA) candidate, designed to act as a powerful immune enhancer for the treatment of solid tumor malignancies. MCT-485: Another dsRNA therapeutic, still in the discovery phase, which demonstrates tumor cytolytic (cell-destroying) properties, intended for use against diverse cancers. Beyond drug candidates, MultiCell Technologies is also progressing the Ideal BioStent, an innovative bioabsorbable stent specifically engineered for use in interventional cardiology and peripheral vessel procedures. The organization maintains licensing agreements with prominent entities such as Corning Incorporated and Pfizer Inc. Established in 1962, the company was previously known as Exten Industries, Inc. before officially changing its name to MultiCell Technologies, Inc. in April 2004. Its corporate headquarters are situated in Woonsocket, Rhode Island.
Aksjekurs
$0.00001
Sist synkronisert: 2026-09-10
Markedsverdi
$50.01K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel MultiCell Technologies, Inc. (MCET)

Kategori

Driftsmargin for MultiCell Technologies, Inc. (MCET)
Driftsmargin per September 2026 TTM: -1,465.60%
Ifølge MultiCell Technologies, Inc. sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) -1,465.60%. Ved slutten av 2013 hadde selskapet en driftsmargin på -2,773.89%.
Historikk for driftsmargin for MultiCell Technologies, Inc. fra 2013 til 2026
Driftsmargin ved slutten av hvert år
År Driftsmargin Endre
2026 (TTM) -1,465.60% 0.00%
2014 -1,465.60% -47.16%
2013 -2,773.89% 0.00%
Driftsmargin for lignende selskaper eller konkurrenter
Selskap Driftsmargin Forskjell i driftsmargin Land
38.59% -100.03%
US
28.81% -100.02%
NL
-149.01% -99.90%
US
25.57% -100.02%
AU
0.00% -
CH
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.